HCG joins hands with Stanford varsity to offer outcome-based cancer treatment

Stanford University, California, will collaborate with Healthcare Global Enterprises (HCG), the cancer care specialist, to implement evidence-based solution for cancer treatment.

Cancer accounted for an estimated 9.6 million deaths in 2018 and globally India is among the top three countries in terms of cancer incidences and mortality.

HCG in association with Jayanta Bhattacharya, professor of medicine at Stanford University, will work in the area of precision medicine by making calculated and organised start into evaluating Indian cancer care data collated over the years. This outcome-based method has already been implemented by Stanford University in the US.

The wealth of data resting with HCG, which includes predictive analysis, outcomes and patient’s response to a particular form of treatment, would be used to analyse and measure pointers that will offer the best course of treatment for a patient.

“India and the US have similar issues in healthcare and it is all about providing treatment that has monetary value to the patient. Enforcing a link between cost and outcome is very important in a low resource environment like India. Data is the right way to go and when analysed correctly, this data would help us reach the desired outcomes,” Bhattacharya said.

According to reports from the World Health Organization, approximately 70 per cent of deaths from cancer occured in low- and middle-income countries. More than 90 per cent of high-income countries reported treatment services compared to less than 30 per cent of low-income countries.

“This is a very important and strategic association for us. It is now time to migrate from expensive treatments to a model where cost and outcomes are measured, said BS Ajaikumar, Chairman, HCG.